What actually disqualifies a private company from a SPAC deal? Patrick Sturgeon says the answer is often the same thing that would sink a traditional IPO — size. A single-asset biotech at Phase 1B with a sub-$100M valuation "just should not be a public company," and the exchanges are taking a harder look at microcaps trying to list.

In this episode, Chaz Churchwell sits down with Dimitre Genov, Managing Director, and Patrick Sturgeon, Managing Partner at Brookline Capital Markets, for a practitioner's breakdown of what separates a strong SPAC target from a costly mistake. They unpack why SPACs win where IPOs can't — complex corporate transactions, international uplistings, and hard tech that needs a longer investor-education runway — plus the rights-versus-warrants trade-off, overhang, transaction deadlines, and why public-company readiness (PCAOB audits, board, service providers) determines whether a deal closes or dies on the calendar.

What We Cover:
 🎯 The size and stage thresholds that disqualify a target
 🧬 Why single-asset early-stage biotech struggles — and where GLP-1s change the math
 🌍 SPACs for spinoffs, post-reorg equity, and international uplistings
 ⚡ Hard tech and the investor-education runway IPOs can't offer
 📊 Rights vs. warrants: dilution, liquidity, and overhang explained
 ⏱️ Transaction deadlines and the cost of blowing a timeline
 ✅ Public-company readiness before you ever talk to a SPAC
 💡 What the best sponsors bring beyond capital, post-close

Connect with Dimitre Genov:
 LinkedIn linkedin.com/in/dimitre-genov-6136182
SPAC & Forth newsletter linkedin.com/newsletters/spac-forth-7395846241579847680

Connect with Patrick Sturgeon:
 Website brooklinecapmkts.com
 LinkedIn linkedin.com/in/patrickasturgeon

Connect with Chaz Churchwell:
 LinkedIn linkedin.com/in/chazchurchwell

Protect Your Transaction: Churchwell Insurance Agency specializes in D&O, E&O, representations and warranties, and public company liability for SPAC sponsors, DESPAC targets, and post-merger companies. https://www.churchwellagency.com/

The DESPAC Podcast is for informational and educational purposes only. Nothing in this content constitutes legal, investment, tax, or financial advice, nor a recommendation to pursue or avoid any transaction. Consult qualified legal, financial, and tax professionals before acting on any information discussed. 

News Theme 1 by Audionautix is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/

THE DESPAC PODCAST  DISCLAIMER

The DESPAC Podcast is for informational purposes only. The views and opinions expressed by the host and guests are their own and do not represent the views of One Iron Network LLC, its affiliates, or any sponsoring organization.

Nothing in this podcast should be interpreted as legal advice, investment advice, tax advice, or a recommendation to pursue or avoid any transaction. Discussions may reference SPACs, DESPAC transactions, securities regulations, or public-company readiness frameworks. These conversations are educational in nature and should not be relied upon when making financial or strategic decisions.

Listeners should consult qualified legal, financial, and tax professionals before acting on any information discussed in this podcast. Any examples or scenarios mentioned are illustrative and may not reflect current market conditions or regulatory requirements.

Participation by a guest does not constitute an endorsement of any company, strategy, product, or service. References to specific firms or individuals are for context only.

One Iron Network LLC and the DESPAC Podcast disclaim all liability arising from the use of or reliance on the information presented.